Condition: Vitamin B12 Deficiency · Sponsor: Medice Arzneimittel Pütter GmbH & Co KG
Primary efficacy objective: To investigate the effects of a parenterally vitamin B12 combination treatment versus an oral vitamin B12 mono therapy on the vitamin B12 status in female and male patients as determined by the change from baseline in serum vitamin B12 concentration after 4 weeks (28 days) of treatment. Secondary efficacy objectives: To evaluate the effects of a parenterally vitamin B12 combination versus an oral vitamin B12 mono therapy after 4 weeks of treatment on: * Serum holotranscobalamin * Serum homocysteine * Serum methylmalonic acid * Combined vitamin B12 markers (cB12) * Serum folic acid * Serum vitamin B6 * Serum S-adenosylmethione (SAM) * Serum S-adenosylhomocysteine (SAH) * SAM/SAH ratio * WHO-5 Well-Being Index * Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) * Visual analogue scale (VAS) EQ-5D. Safety objectives: To evaluate the safety and tolerability of oral vitamin B12 mono therapy versus intramuscular vitamin B12 combination.
This description comes directly from the study's public registry record.
Igor Zupanets, Prof.Dr. · +380679093809 · igorzupanets@gmail.com
Tetyana Kolodyezna, PhD · +380937387790 · kolodeznaya@aisconsulting.com.ua
Always discuss trial participation with your own doctor first.
| State institution "V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine" | Kharkiv, Ukraine | Recruiting |
| Private Enterprise Private Manufacturing Company "Acinus" | Kropyvnytskyi, Ukraine | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07029698